Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXS6837 in Primary IgA Nephropathy
NCT07502638Phase 2Not yet recruiting
- Sponsor
- Fosun Pharma
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FXS6837 in IgA nephropathy (IgAN), sponsored by Fosun Pharma. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
FXS6837
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07502638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502638.